$GH

Kalia Kumud purchased $78K of GH

Kalia Kumud (Chief Information Officer) purchased 600 shares of Guardant Health, Inc. (GH) at $130.76 on 2026-06-15.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 30, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Bullish
medium confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHBullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase by the company’s CIO, which may slightly influence sentiment but is not a fundamental update.

02

Market read

Traders may note the insider buy as a small positive sentiment datapoint, but it is unlikely to drive a major repricing alone.

03

What to watch

The filing does not indicate intent beyond the disclosed buy; without follow-on buys/sells or a larger transaction size, signal strength is limited.

Relevance 4/10Novelty 5/10Timing: new Form 4 filed 2026-06-30 (covers 2026-06-15 purchase)

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHBullishMedium confidence
Context

Guardant Health CIO Kalia Kumud filed a Form 4 open-market purchase of 600 shares at $130.76 on 2026-06-15.

Expected impact

Likely limited near-term impact; any reaction would be small and short-lived unless followed by additional disclosures.

Evidence & confidence

The transaction is a routine officer open-market buy (no 10b5-1 plan), but the dollar size (~$78k) is not large enough to be a standalone catalyst.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Officer purchases can be driven by personal liquidity needs, diversification, or routine compensation-related activity rather than a strong forward view.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Kalia Kumud

    Chief Information Officer who purchased 600 shares open-market at $130.76.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.